BML-210
HDAC inhibitor / A novel non-hydroxamic acid HDAC inhibitor. IC50=5-10 µM (HeLa nuclear extract). Induces growth inhibition, proapoptotic and differentiation effects on human leukemia cell lines.
Biochemicals & reagents
537034-17-6
1) Savickiene, et al. (2006), The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines. Eur. J. Pharmacol. 549 9 / 2) Herman, et al. (2006), Histone deacetylase inhibitors reverse gene silencing in Friedreich’s ataxia. Nature Chem. Biol. 10 551
-20°C
TARGET: Protein deacetylase -- PATHWAY: Chromatin; Apoptosis inducer; Posttranslational modification; Proliferation -- RESEARCH AREA: Epigenetics; Cell death -- DISEASE AREA: Cancer